Drug
Sar302503
Sar302503: highest development phase Phase 3, developed by Bristol-Myers Squibb. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Bristol-Myers Squibb
Trials
| Drug | Phase | Indication |
|---|---|---|
| SAR302503 NCT01437787 | Phase 3 | Hematopoietic Neoplasm |
Latest
No recent events.
Follow Sar302503 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.